Techniques in Regional Anesthesia & Pain Management
Volume 14, Issue 2 , Pages 42-47 , April 2010

Voltage-gated calcium channels and pain

  • Lisa Doan, MD

      Affiliations

    • Corresponding Author InformationAddress reprint requests and correspondence: Lisa Doan, MD, Department of Anesthesiology, NYU Langone Medical Center, 317 E. 34th St, Ste. 902, New York, NY 10016

References 

  1. Hardt J, Jacobsen C, Goldberg J, et al. Prevalence of chronic pain in a representative sample in the United States. Pain Med. 2008;9:803–812
  2. Ohayon MM, Schatzberg AF. Chronic pain and major depressive disorder in the general population. J Psychiatr Res. 2010;(in press)
  3. Catterall WA. Structure and regulation of voltage-gated Ca channels. Annu Rev Cell Dev Biol. 2000;16:521–544
  4. Perez-Reyes E, Sim HS, Lacerda AE, et al. Induction of calcium currents by the expression of the A1-subunit of the dihydropyridine receptor from skeletal muscle. Nature. 1989;340:233–236
  5. Varadi G, Lory P, Schultz D, et al. Acceleration of activation and inactivation by the b sununit of the skeletal muscle calcium channel. Nature. 1991;352:159–162
  6. Singer D, Biel M, Lotan I, et al. The roles of the subunits in the function of the calcium channel. Science. 1991;253:1553–1667
  7. Chu PJ, Robertson HM, Best PM. Calcium channel γ subunits provide insights into the evolution of this gene family. Gene. 2001;280:37–48
  8. Westenbroek RE, Hell JW, Warner C, et al. Biochemical properties and subcellular distribution of an N-type calcium channel alpha 1 subunit. Neuron. 1992;9:1099–1115
  9. Maggi CA, Tramontana M, Cecconi R, et al. Neurochemical evidence for the involvement of N-type calcium channels in transmitter secretion from peripheral endings of sensory nerves in Guinea pigs. Neurosci Lett. 1990;114:203–206
  10. Berridge MJ, Lipp P, Bootman MD. The versatility and universality of calcium signalling. Nat Rev Mol Cell Biol. 2000;1:11–21
  11. Seward E, Hammond C, Henderson G. m-opioid-receptor-mediated inhibition of the N-type calcium-channel current. Proc R Soc Lond B. 1991;244:129–135
  12. Bourinet E, Soong TW, Stea A, et al. Determinants of the G protein-dependent opioid modulation of neuronal calcium channels. Proc Natl Acad Sci U S A. 1996;93:1486–1491
  13. Olivera BM, McIntosh JM, Cruz FA, et al. Purification and sequence of a presynaptic peptide toxin from Conus geographus venom. Biochimie. 1984;23:5087–5090
  14. Olivera BM, Cruz LJ, de Santos V, et al. Neuronal calcium channel antagonists (Discrimination between calcium channel subtypes using omega-conotoxin from conus Magus venom). Biochimie. 1987;26:2086–2090
  15. Chaplan SR, Pogrel JW, Yaksh TL. Role of voltage-dependent calcium channel subtypes in experimental tactile allodynia. J Pharmacol Exp Ther. 1994;269:1117–1123
  16. Diaz A, Dickenson AH. Blockade of spinal N- and P-type, but not L-type, calcium channels inhibits the excitability of rat dorsal horn neurones produced by subcutaneous formalin inflammation. Pain. 1997;69:93–100
  17. Matthews EA, Dickenson AH. Effects of spinally delivered N- and P-type voltage-dependent calcium channel antagonists on dorsal horn neuronal responses in a rat model of neuropathy. Pain. 2001;92:235–246
  18. Evans AR, Nicol GD, Vasko MR. Differential regulation of evoked peptide release by voltage-sensitive calcium channels in rat sensory neurons. Brain Res. 1996;18:265–273
  19. Zieglgansberger W, Tulloch IF. Effects of substance P on neurones in the dorsal horn of the spinal cord of the cat. Brain Res. 1979;166:273–282
  20. Kuraishi Y, Hirota N, Sato Y, et al. Evidence that substance P and somatostatin transmit separate information related to pain in the spinal dorsal horn. Brain Res. 1985;325:294–298
  21. Piercey MF, Moon MW, Blinn JR, et al. Analgesic activities of spinal cord substance P antagonists implicate substance P as a neurotransmitter of pain sensation. Brain Res. 1986;385:74–85
  22. Oku R, Satoh M, Fujii N, et al. Calcitonin gene-related peptide promotes mechanical nociception by potentiating release of substance P from the spinal dorsal horn in rats. Brain Res. 1987;403:350–354
  23. Saegusa H, Kurihara T, Zong S, et al. Supression of inflammatory and neuropathic pain symptoms in mice lacking the N-type Ca2+ channel. EMBO J. 2001;20:2349–2356
  24. Lipscombe D, Pan JQ, Gray AC. Functional diversity in neuronal voltage-gated calcium channels by alternative splicing of Ca(v)alpha1. Mol Neurobiol. 2002;26:21–44
  25. Bell TJ, Thaler C, Castiglioni AJ, et al. Cell-specific alternative splicing increases calcium channel current density in the pain pathway. Neuron. 2004;41:127–138
  26. Altier C, Dale CS, Kisilevsky AE, et al. Differential role of N-type calcium channel Splice isoforms in pain. J Neurosci. 2007;27:6363–6373
  27. Atanassoff PG, Hartmannsgruber MW, Thrasher J, et al. Ziconotide, a new N-type calcium channel blocker, administered intrathecally for acute postoperative pain. Reg Anesth Pain Med. 2000;25:274–278
  28. Staats PS, Yearwood T, Charapata SG, et al. Intrathecal ziconotide in the treatment of refractory pain in patients with cancer or AIDS. J Am Med Assoc. 2004;291:64–70
  29. Rauck RL, Wallace MS, Leong MS, et al. A randomized, double-blind, placebo-controlled study of intrathecal ziconotide in adults with severe chronic pain. J Pain Symptom Manage. 2006;31:393–406
  30. Wallace MS, Kosek PS, Staats P, et al. Phase II, open-label, multicenter study of combined intrathecal morphine and ziconotide: Addition of ziconotide in patients receiving intrathecal morphine for severe chronic pain. Pain Med. 2008;9:271–281
  31. Webster LR, Fakata KL, Charapata S, et al. Open-label, multicenter study of combined intrathecal morphine and ziconotide: Addition of morphine in patients receiving ziconotide for severe chronic pain. Pain Med. 2008;9:282–290
  32. McGuire D, Bowersox S, Fellmann JD, et al. Sympatholysis after neuron-specific, N-type, voltage-sensitive calcium channel blockade: First Demonstration of N-channel function in human. J Cardiovasc Pharmacol. 1997;30:400–403
  33. Bowersox SS, Singh T, Nadasdi L, et al. Cardiovascular effects of ω-conopeptides in conscious rats: Mechanisms of action. J Cardiovasc Pharmacol. 1992;20:756–764
  34. Smith MT, Cabot PJ, Ross FB, et al. The novel N-type calcium channel blocker, AM336, produces potent dose-dependent antinociception after intrathecal dosing in rats and inhibits substance P release in rat spinal cord slices. Pain. 2002;96:119–127
  35. Scott DA, Wright CE, Angus JA. Actions of intrathecal omega-conotoxins CVID, GVIA, MVIIA, and morphine in acute and neuropathic pain in the rat. Eur J Pharmacol. 2002;451:279–286
  36. Sharp D. Novel pain relief via marine snails. Lancet. 2005;366:439–440
  37. Wright CE, Robertson AD, Whorlow SL, et al. Cardiovascular and autonomic effects of ω-conotoxins MVIIA and CVID in conscious rabbits and isolated tissue assays. Br J Pharmacol. 2000;131:1325–1336
  38. Kolosov A, Goodchild CS, Cooke I. CNSB004 (Leconotide) causes Antihyperalgesia without side effects when given intravenously: A comparison with ziconotide in a rat model of diabetic neuropathic pain. Pain Med. 2010;11:262–273
  39. Yunkger AR, McEnery MW. Low-voltage-activated (“T-Type”) calcium channels in review. J Bioenerg Biomembr. 2003;35:533–575
  40. Magee JC, Christofi G, Miyakawa H, et al. Subthreshold synaptic activation of voltage-gated Ca2+ channels mediates a localized Ca2+ influx into the dendrites of hippocampal pyramidal neurons. J Neurophysiol. 1995;74:1335–1342
  41. Huguenard JR. Low-threshold calcium currents in central nervous system neurons. Annu Rev Physiol. 1996;58:329–348
  42. Matthews EA, Dickenson AH. Effects of ethosuximide, a T-type Ca2+ channel blocker, on dorsal horn neuronal responses in rats. Eur J Pharmacol. 2001;415:141–149
  43. Jagodic MM, Pathirathna S, Nelson MT, et al. Cell-specific alterations of T-type calcium current in painful diabetic neuropathy enhance excitability of sensory neurons. J Neurosci. 2007;27:3305–3316
  44. Jagodic MM, Pathirathna S, Joksovic PM, et al. Up-regulation of the T-type calcium current in small rat sensory neurons after chronic constrictive injury of the sciatic nerve. J Neurophysiol. 2008;99:3151–3156
  45. Bourinet E, Alloui A, Monteil A, et al. Silencing of the Cav3.2 T-type calcium channel gene in sensory neurons demonstrates its major role in nociception. EMBO J. 2005;24:315–324
  46. Wen XJ, Li ZJ, Chen ZX, et al. Intrathecal administration of Cav3.2 and Cav3.3 antisense oligonucleotide reverses tactile allodynia and thermal hyperalgesia in rats following chronic compression of dorsal root of ganglion. Acta Pharmacol Sin. 2006;27:1547–1552
  47. Choi S, Na HS, Kim J, et al. Attenuated pain responses in mice lacking Cav3.2 T-type channels. Genes Brain Behav. 2007;6:425–431
  48. Na HS, Choi S, Kim J, et al. Attenuated neuropathic pain in Cav3.1 null mice. Mol Cells. 2008;25:242–246
  49. Kim D, Park D, Choi S. Thalamic control of visceral nociception mediated by T-type Ca2+ channels. Science. 2003;302:117–119
  50. Dogrul A, Gardeli LR, Ossipov MH, et al. Reversal of experimental neuropathic pain by T-type calcium channel blockers. Pain. 2003;105:159–168
  51. Flatters SJ, Bennett GJ. Ethosuximide reverses paclitaxel- and vincristine-induced painful peripheral neuropathy. Pain. 2004;109:150–161
  52. Barton ME, Eberle EL, Shannon HE. The antihyperalgesic effects of the T-type calcium channel blockers ethosuximide, trimethadione, and mibefradil. Eur J Pharmacol. 2005;521:79–85
  53. Gören MZ, Filiz O. Ethosuximide: From bench to bedside. CNS Drug Res. 2007;13:224–239
  54. Fossat P, Dobremez E, Bouali-Benazzouz R, et al. Knockdown of L calcium channel subtypes: Differential effects in neuropathic pain. J Neurosci. 2010;30:1073–1085
  55. Westenbroek RE, Hoskins L, Catterall WA. Localization of Ca2+ channel subtypes on rat spinal motor neurons, interneurons, and nerve terminals. J Neurosci. 1998;18:6319–6330
  56. Fukumoto N, Obama Y, Kitamura N, et al. Hypoalgesic behaviors of P/Q-type voltage-gated Ca2+ channel mutant mouse, rolling mouse Nagoya. Neuroscience. 2009;160:165–173
  57. Murakami M, Nakagawasai O, Suzuki T, et al. Antinociceptive effect of different types of calcium channel inhibitors and the distribution of various calcium channel α1 subunits in the dorsal horn of spinal cord in mice. Brain Res. 2004;1024:122–129
  58. Saegusa H, Kurihara T, Zong S, et al. Altered pain responses in mice lacking α1E subunit of the voltage-dependent Ca2+ channel. Proc Natl Acad Sci USA. 2000;97:6132–6137
  59. Newcomb R, Szoke B, Palma A, et al. Selective peptide antagonist of the class E calcium channel from the venom of the tarantula Hysterocrates gigas. Biochimie. 1998;37:15353–15362
  60. Matthews EA, Bee LA, Stephens GJ, et al. The Cav2.3 calcium channel antagonist SNX-482 reduces dorsal horn neuronal responses in a rat model of chronic neuropathic pain. Eur J Neurosci. 2007;25:3561–3569
  61. Satzinger G. Antiepileptics from gamma-aminobutyric acid. Arzneim Forsch. 1994;44:261–266
  62. Hoekstra MS, Sobieray DM, Schwindt MA, et al. Chemical development of CI-1008, an enantiomerically pure anticonvulsant. Org Proc Res Dev. 1997;1:26–38
  63. Meldrum BS. GABAergic mechanisms in the pathogenesis of epilepsy. Br J Clin Pharmacol. 1989;27:3S–11S
  64. Gee NS, Brown JP, Dissanayake VUK, et al. The novel anticonvulsant drug, gabapentin (Neurontin), binds to the α2δ subunit of a calcium channel. J Biol Chem. 1996;271:5768–5776
  65. Taylor CP, Gee NS, Su T-Z, et al. A summary of mechanistic hypotheses of gabapentin pharmacology. Epilepsy Res. 1998;29:231–246
  66. Rosner H, Rubin L, Kestenbaum A. Gabapentin adjunctive therapy in neuropathic pain states. Clin J Pain. 1996;12:56–58
  67. Mellick GA, Mellick LB. Reflex sympathetic dystrophy treated with gabapentin. Arch Phys Med Rehabil. 1997;78:98–105
  68. Hwang JH, Yaksh TL. Effect of subarachnoid gabapentin on tactile-evoked allodynia in a surgically induced neuropathic pain model in the rat. Reg Anesth Pain Med. 1997;22:249–256
  69. Brust PF, Simerson S, McCue AF, et al. Human neuronal voltage-dependent calcium channels: Studies on subunit structure and role in channel assembly. Neuropharmacology. 1993;32:1089–1102
  70. Yusaf SP, Goodman J, Pinnock RD, et al. Expression of voltage-gated calcium channel subunits in rat dorsal root ganglion neurons. Neurosci Lett. 2001;311:137–141
  71. Marais E, Klugbauer N, Hofmann F. Calcium channel α2δ subunits—Structure and gabapentin binding. Mol Pharmacol. 2001;59:1243–1248
  72. Luo ZD, Chaplan SR, Higuera ES, et al. Upregulation of dorsal root ganglion α2δ calcium channel subunit and its correlation with allodynia in spinal nerve-injured rats. J Neurosci. 2001;21:1868–1875
  73. Luo ZD, Calcutt NA, Higuera ES, et al. Injury type-specific calcium channel α2δ-1 subunit up-regulation in rat neuropathic pain models correlates with antiallodynic effects of gabapentin. J Pharmacol Exp Ther. 2002;303:1199–1205
  74. Li C-Y, Song Y-H, Higuera ES, et al. Spinal dorsal horn calcium channel α2δ -1 subunit upregulation contributes to peripheral nerve injury-induced tactile allodynia. J Neurosci. 2004;24:8494–8499
  75. Li C-Y, Zhang X-L, Matthews E, et al. Calcium channel α2δ1 subunit mediates spinal hyperexcitability in pain modulation. Pain. 2006;125:20–31
  76. Field MJ, Holloman EF, McCleary S, et al. Evaluation of gabapentin and S-(+)-isobutyl GABA in a rat model of postoperative pain. J Pharmacol Exp Ther. 1997;282:1242–1246
  77. Field MK, Oles RJ, Lewis AS, et al. Gabapentin (Neurontin) and S-(+)-3-isobutyl GABA represent a novel class of selective anti-hyperalgesic agents. Br J Pharmacol. 1997;121:1513–1522
  78. Hendrich J, Minh ATV, Heblich F, et al. Pharmacological disruption of calcium channel trafficking by the α2δ ligand gabapentin. Proc Natl Acad Sci USA. 2008;105:3628–3633
  79. Bauer CS, Nieto-Rostro M, Rahman W, et al. The increased trafficking of the calcium channel subunit α2δ-1 to presynaptic terminals in neuropathic pain is inhibited by the a2d ligand Pregabalin. J Neurosci. 2009;29:4076–4088
  80. Vega-Hernandez A, Felix R. Down-regulation of N-type voltage-activated channels by gabapentin. Cell Mol Neurobiol. 2002;22:185–190
  81. Bayer K, Ahmadi S, Zeilhofer HU. Gabapentin may inhibit synaptic transmission in the mouse spinal cord dorsal horn through a preferential block of P/Q-type calcium channels. Neuropharmacology. 2004;46:743–749
  82. Dworkin RH, O'Connor AB, Backonja M, et al. Pharmacologic management of neuropathic pain: Evidence-based recommendations. Pain. 2007;132:237–251
  83. Crofford LJ, Rowbotham MC, Mease PJ, et al. Pregabalin for the treatment of fibromyalgia syndrome: Results of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2005;52:1264–1273
  84. Mease PJ, Russel IJ, Arnold LM, et al. A randomized, double-blind, placebo-controlled, phase III trial of Pregabalin in the treatment of patients with fibromyalgia. J Rheumatol. 2008;35:502–514

PII: S1084-208X(10)00020-0

doi: 10.1053/j.trap.2010.03.003

Techniques in Regional Anesthesia & Pain Management
Volume 14, Issue 2 , Pages 42-47 , April 2010

Article Tools

* Image Usage & Resolution